Oral trans-mucosal administration of ticagrelor: is this really the future?

Fabiana Rollini; Francesco Franchi; Dominick J. Angiolillo

doi:10.1160/TH17-03-0177

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2017; 117(05): 826-828
DOI: 10.1160/TH17-03-0177

Invited Editorial Focus

Schattauer GmbH

Oral trans-mucosal administration of ticagrelor: is this really the future?

Fabiana Rollini

¹University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA

,

Francesco Franchi

¹University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA

,

Dominick J. Angiolillo

¹University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68: 1082-1115.
2 Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12: 30-47.
3 Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol. 2017 Epub ahead of print.
4 Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010; 08: 151-158.
5 Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 2012; 72: 2087-2116.
6 Storey RF, Angiolillo DJ, Patil SB. et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456-1462.
7 Wallentin L, Becker RC, Budaj A. et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
8 Alexopoulos D, Xanthopoulou I, Gkizas V. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 05: 797-804.
9 Parodi G, Valenti R, Bellandi B. et al. Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study. J Am Coll Cardiol 2013; 61: 1601-1606.
10 Franchi F, Rollini F, Cho JR. et al. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. JACC Cardiovasc Interv 2015; 08: 1457-1467.
11 Osmancik P, Jirmar R, Hulikova K. et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75: 158-166.
12 Rollini F, Franchi F, Angiolillo DJ. Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention. EuroIntervention 2017; 12: 1681-1683.
13 Parodi G, Bellandi B, Xanthopoulou I. et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014; 08 pii e001593
14 Kubica J, Adamski P, Ostrowska M. et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252.
15 Rollini F, Franchi F, Hu J. et al. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. J Am Coll Cardiol 2016; 67: 1994-2004.
16 Parodi G, Xanthopoulou I, Bellandi B. et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol 2015; 65: 511-512.
17 Venetsanos D, Sederholm Lawesson S, Swahn E, Alfredsson J. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res 2017; 149: 88-94.
18 Asher E, Frydman S, Katz M. et al. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. Thromb Haemost 2017; 117: 727-733.
19 Niezgoda P, Sikora J, Baranska M. et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina- a pharmacokinetic /pharmacodynamic study. Thromb Haemost 2017; 117: 718-726.
20 Satheesh Madhav NV, Semwal R, Semwal DK. et al. Recent trends in oral transmucosal drug delivery systems: an emphasis on the soft palatal route. Expert Opin Drug Deliv 2012; 09: 629-647.